ClinicalTrials.gg
CompletedNCT06911203Updated Oct 13, 2026

A Study of BGM0504 in Participants With Obesity

A Phase 2 interventional study of BGM0504 and Tirzepatide in Obesity, sponsored by BrightGene Bio-Medical Technology Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by BrightGene Bio-Medical Technology Co., Ltd. · Phase 2, Interventional, and Treatment

Updated Oct 13, 2026Now CompletedStart date moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
96
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing BGM0504 in Obesity — none open to participants now, none under way, none of them phase 3. BGM0504 · Obesity.

Enrollment
4th of 10
96 · median 78
Started
2025
with 5 others
Phase 2
3 of 10
none open now
Registered
4th of 10
by date
Lead sponsor
8 of 10
BrightGene Bio-Medical Technology Co., Ltd.

Among the 10 studies testing BGM0504 in Obesity, this one is the 4th largest by enrollment, is one of 6 that started in 2025, is one of 3 in phase 2, and was the 4th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

None of the 10 studies testing BGM0504 in Obesity is open now. The open studies under Obesity, anywhere →

Where they have run

About BGM0504

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies testing BGM0504 in Obesity as a file.
02

Study summary

To evaluate the efficacy and safety of BGM0504 compared with Tirzepatide in adult participants who have obesity without diabetes after 26 weeks of treatment.

03

Conditions studied

  • Obesity

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ● Able and willing to provide a written .

    • Male or female subjects, 18-65 years of age at the time of signing informed consent.
    • At screening visit, 35.0 ﹤﹤ 45.0 kg/m2;
    • Diet and exercise control for at least 3 months before screening visit, and be of stable weight (± 5%) self-reported change within the last 3 months.

Exclusion criteria

Exclusion Criteria:

  • ●History of chronic or acute pancreatitis.

    • History of severe drug allergy or specific allergic disease or severe allergies.
    • Family or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2(MEN-2).
    • History of malignant tumors [except carcinoma in situ with no recurrence within 5 years (except for malignant melanoma in situ), skin basal cell carcinoma and squamous cell carcinoma].
    • Suspected or confirmed history of alcohol or drug abuse;
    • Any chronic infections likely to interfere with study conduct or interpretation such as (HBV), (HCV), (HIV) or treponema pallidum (TP).
    • Donation or loss of 400 mL or more of blood within 3 months prior to screening, or blood donation during screening or within 3 months after the end of the trial.
    • Pregnant or lactating woman.
    • Any disorder, unwillingness, or inability not covered by any of the other exclusion criteria, which in the Investigator's opinion, might jeopardize the participant's safety or compliance with the protocol.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
96 participants (actual)

Study arms

  • Experimental
    BGM0504

    Participants will receive BGM0504 subcutaneously(SC).

    Drug: BGM0504

  • Active comparator
    Tirzepatide

    Paritcipants will receive tirzepatide SC.

    Drug: Tirzepatide

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Body Weight

    Change from baseline in body weight after 26 weeks of treatment

    Time frame: Week 0, Week 26

Secondary outcomes

  1. Change From Baseline in BMI

    Change from baseline in BMI after 26 weeks of treatment

    Time frame: Week 18, Week 26

  2. Change From Baseline in Waist Circumference

    Change from baseline in waist circumference after 26 weeks of treatment

    Time frame: Week 18, Week 26

  3. Change from Baseline in Systolic Blood Pressure (SBP)

    Change from Baseline in SBP after 26 weeks of treatment

    Time frame: Week 18, Week 26

  4. Change from Baseline in Diastolic Blood Pressure (DBP)

    Change from Baseline in DBP after 26 weeks of treatment

    Time frame: Week 18, Week 26

  5. Change from Baseline in Impact of Weight on Quality of Life-Lite Clinical Trials Version (IWQOL-Lite-CT)

    Change from Baseline in IWQOL-Lite-CT after 26 weeks of treatment

    Time frame: Week 0, Week 26

07

Study locations

1 site
  • Peking University People's Hospital
    Beijing, Beijing Municipality 100044, China
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2025 to primary completion in Jan 2026, 9 months.

Of 176 industry-sponsored phase 2 interventional studies under Obesity, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 18. This study's 9 months is below that.

Counting every sponsor, half of 307 studies reached it within 16 months; a quarter within 10 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 3, 2025
First posted
Apr 4, 2025
StartActual
Apr 9, 2025
Primary completionActual
Jan 14, 2026
CompletionActual
Jan 14, 2026
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Oct 13, 2026
Start date
Apr 3, 2025→Apr 9, 2025
Oct 13, 2026
Primary completion
Jan 11, 2026→Jan 14, 2026 (actual)
Oct 13, 2026
Study completion
Jan 11, 2026→Jan 14, 2026 (actual)
Oct 13, 2026
Enrollment
90 (estimated)→96 (actual)
Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    Recruiting→Completed
    Start date Apr 3, 2025→Apr 9, 2025
    Primary completion Jan 11, 2026→Jan 14, 2026 (now actual)
    Study completion Jan 11, 2026→Jan 14, 2026 (now actual)
    Enrollment 90 (estimated)→96 (actual)
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06911203
Responsible party
Sponsor
First posted
Apr 4, 2025
Start date
Apr 9, 2025
Primary completion
Jan 14, 2026
Completion
Jan 14, 2026
Last update
Oct 13, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: BGM0504

Start the discussion